---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-100646"
form_type: "8-K"
ticker: "CYPH"
cik: "0001509745"
company_name: "CYPHERPUNK TECHNOLOGIES INC."
filed_at: "2025-10-20T23:59:59+00:00"
generated_at: "2026-05-17T03:13:11.623116+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Leap's sirexatamab shows statistically significant PFS/OS benefit in DKK1-high CRC at ESMO 2025

## Summary
- In DKK1-high (upper median, n=88): mPFS 9.03 vs 7.06 mo (HR 0.61, p=0.0255); mOS not reached vs 14.39 mo (HR 0.42, p=0.0118).
- In DKK1-high (upper quartile, n=44): mPFS 9.36 vs 5.88 mo (HR 0.46, p=0.017); mOS not reached vs 9.66 mo (HR 0.17, p<0.001).
- Full ITT (n=188): mPFS 9.2 vs 8.3 mo (HR 0.84, p=0.171); ORR 35.1% vs 26.6%.
- Sirexatamab well tolerated; TEAE profile similar between arms.
- Leap plans to engage regulators on registrational path for sirexatamab in CRC; supported by recent financing.

## SEC filing metadata
- accession: 0001104659-25-100646
- form_type: 8-K
- ticker: CYPH
- cik: 0001509745
- company_name: CYPHERPUNK TECHNOLOGIES INC.
- filed_at: 2025-10-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509745/000110465925100646/0001104659-25-100646-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509745/000110465925100646/tm2529085d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-100646
- JSON: https://secwatch.observer/filing/0001104659-25-100646.json
- Plain text: https://secwatch.observer/filing/0001104659-25-100646.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.